645 related articles for article (PubMed ID: 25358480)
1. Evaluating the potential impact of a reformulated version of oxycodone upon tampering, non-adherence and diversion of opioids: the National Opioid Medications Abuse Deterrence (NOMAD) study protocol.
Degenhardt L; Larance B; Bruno R; Lintzeris N; Ali R; Farrell M
Addiction; 2015 Feb; 110(2):226-37. PubMed ID: 25358480
[TBL] [Abstract][Full Text] [Related]
2. The introduction of a potentially abuse deterrent oxycodone formulation: Early findings from the Australian National Opioid Medications Abuse Deterrence (NOMAD) study.
Degenhardt L; Bruno R; Ali R; Lintzeris N; Farrell M; Larance B
Drug Alcohol Depend; 2015 Jun; 151():56-67. PubMed ID: 25910850
[TBL] [Abstract][Full Text] [Related]
3. The effect of a potentially tamper-resistant oxycodone formulation on opioid use and harm: main findings of the National Opioid Medications Abuse Deterrence (NOMAD) study.
Larance B; Dobbins T; Peacock A; Ali R; Bruno R; Lintzeris N; Farrell M; Degenhardt L
Lancet Psychiatry; 2018 Feb; 5(2):155-166. PubMed ID: 29336948
[TBL] [Abstract][Full Text] [Related]
4. Sustained reduction of diversion and abuse after introduction of an abuse deterrent formulation of extended release oxycodone.
Severtson SG; Ellis MS; Kurtz SP; Rosenblum A; Cicero TJ; Parrino MW; Gilbert MK; Buttram ME; Dasgupta N; BucherBartelson B; Green JL; Dart RC
Drug Alcohol Depend; 2016 Nov; 168():219-229. PubMed ID: 27716575
[TBL] [Abstract][Full Text] [Related]
5. Attractiveness of reformulated OxyContin(R) tablets: assessing comparative preferences and tampering potential.
Sellers EM; Perrino PJ; Colucci SV; Harris SC
J Psychopharmacol; 2013 Sep; 27(9):808-16. PubMed ID: 23784739
[TBL] [Abstract][Full Text] [Related]
6. A typology of people who tamper with pharmaceutical opioids: responses to introduction of a tamper-resistant formulation of controlled-release oxycodone.
Peacock A; Degenhardt L; Larance B; Cama E; Lintzeris N; Ali R; Bruno R
Pharmacoepidemiol Drug Saf; 2015 Dec; 24(12):1321-33. PubMed ID: 26419615
[TBL] [Abstract][Full Text] [Related]
7. Abuse-Deterrent Formulations and the Prescription Opioid Abuse Epidemic in the United States: Lessons Learned From OxyContin.
Cicero TJ; Ellis MS
JAMA Psychiatry; 2015 May; 72(5):424-30. PubMed ID: 25760692
[TBL] [Abstract][Full Text] [Related]
8. Methods and predictors of tampering with a tamper-resistant controlled-release oxycodone formulation.
Peacock A; Degenhardt L; Hordern A; Larance B; Cama E; White N; Kihas I; Bruno R
Int J Drug Policy; 2015 Dec; 26(12):1265-72. PubMed ID: 26123898
[TBL] [Abstract][Full Text] [Related]
9. Protocol: changes in rates of opioid overdose and poisoning events in an integrated health system following the introduction of a formulation of OxyContin® with abuse-deterrent properties.
Janoff SL; Perrin NA; Coplan PM; Chilcoat HD; Campbell CI; Green CA
BMC Pharmacol Toxicol; 2016 May; 17(1):21. PubMed ID: 27177423
[TBL] [Abstract][Full Text] [Related]
10. Abuse of reformulated OxyContin: Updated findings from a sentinel surveillance sample of individuals assessed for substance use disorder.
Cassidy TA; Thorley E; Black RA; DeVeaugh-Geiss A; Butler SF; Coplan P
J Opioid Manag; 2017; 13(6):425-440. PubMed ID: 29308589
[TBL] [Abstract][Full Text] [Related]
11. Decreased diversion by doctor-shopping for a reformulated extended release oxycodone product (OxyContin).
Chilcoat HD; Coplan PM; Harikrishnan V; Alexander L
Drug Alcohol Depend; 2016 Aug; 165():221-8. PubMed ID: 27372220
[TBL] [Abstract][Full Text] [Related]
12. Comparing the Effect of Tampering on the Oral Pharmacokinetic Profiles of Two Extended-Release Oxycodone Formulations with Abuse-Deterrent Properties.
Gudin J; Levy-Cooperman N; Kopecky EA; Fleming AB
Pain Med; 2015 Nov; 16(11):2142-51. PubMed ID: 26108255
[TBL] [Abstract][Full Text] [Related]
13. Incidence of nonmedical use of OxyContin and other prescription opioid pain relievers before and after the introduction of OxyContin with abuse deterrent properties.
Cheng HG; Coplan PM
Postgrad Med; 2018 Aug; 130(6):568-574. PubMed ID: 29978755
[TBL] [Abstract][Full Text] [Related]
14. Opioid use following the introduction of an extended-release oxycodone formulation with tamper-resistant properties: Prospective historical chart review in methadone-maintained patients.
Sankey C; Setnik B; Harsanyi Z; Michalko K; Yang Z; Geoffroy P
J Opioid Manag; 2016; 12(2):149-59. PubMed ID: 27194200
[TBL] [Abstract][Full Text] [Related]
15. The characteristics of a cohort who tamper with prescribed and diverted opioid medications.
Larance B; Lintzeris N; Bruno R; Peacock A; Cama E; Ali R; Kihas I; Hordern A; White N; Degenhardt L
J Subst Abuse Treat; 2015 Nov; 58():51-61. PubMed ID: 26286818
[TBL] [Abstract][Full Text] [Related]
16. Changes in drug use patterns reported on the web after the introduction of ADF OxyContin: findings from the Researched Abuse, Diversion, and Addiction-Related Surveillance (RADARS) System Web Monitoring Program.
Vosburg SK; Haynes C; Besharat A; Green JL
Pharmacoepidemiol Drug Saf; 2017 Sep; 26(9):1044-1052. PubMed ID: 28653782
[TBL] [Abstract][Full Text] [Related]
17. Monitoring of internet forums to evaluate reactions to the introduction of reformulated OxyContin to deter abuse.
McNaughton EC; Coplan PM; Black RA; Weber SE; Chilcoat HD; Butler SF
J Med Internet Res; 2014 May; 16(5):e119. PubMed ID: 24800858
[TBL] [Abstract][Full Text] [Related]
18. Impact of abuse-deterrent OxyContin on prescription opioid utilization.
Hwang CS; Chang HY; Alexander GC
Pharmacoepidemiol Drug Saf; 2015 Feb; 24(2):197-204. PubMed ID: 25393216
[TBL] [Abstract][Full Text] [Related]
19. The effect of an abuse-deterrent opioid formulation (OxyContin) on opioid abuse-related outcomes in the postmarketing setting.
Coplan PM; Chilcoat HD; Butler SF; Sellers EM; Kadakia A; Harikrishnan V; Haddox JD; Dart RC
Clin Pharmacol Ther; 2016 Sep; 100(3):275-86. PubMed ID: 27170195
[TBL] [Abstract][Full Text] [Related]
20. Pharmacy-related theft of controlled substances: RxPATROL® findings.
Erensen JG; Haddox JD; Attre MS; Bauza LN
J Opioid Manag; 2018; 14(5):373-380. PubMed ID: 30387860
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]